CeriBell (NASDAQ:CBLL) Receives $32.60 Average Price Target from Analysts

CeriBell (NASDAQ:CBLL) has earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $32.60.

Several research analysts have issued reports on the stock. William Blair assumed coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating on the stock. TD Cowen raised their price objective on shares of CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. JPMorgan Chase & Co. assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 target price on the stock. Canaccord Genuity Group assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Bank of America assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price on the stock.

CeriBell Trading Up 9.0 %

Shares of CeriBell stock opened at $22.94 on Friday. CeriBell has a 1 year low of $18.69 and a 1 year high of $32.75. The stock’s fifty day simple moving average is $26.02.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. On average, research analysts forecast that CeriBell will post -2.46 EPS for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.